#### Check for updates

#### OPEN ACCESS

EDITED BY Hai-Feng Pan, Anhui Medical University, China

REVIEWED BY Enyew Mekonen, University of Gondar, Ethiopia Manojit Bhattacharya, Fakir Mohan University, India

\*CORRESPONDENCE Getachew Asmare Adella gasmare35@gmail.com

#### SPECIALTY SECTION

This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health

RECEIVED 11 April 2022 ACCEPTED 14 September 2022 PUBLISHED 29 September 2022

#### CITATION

Adella GA, Abebe K, Atnafu N, Azeze GA, Alene T, Molla S, Ambaw G, Amera T, Yosef A, Eshetu K, Yeshambel A, Nigatu D, Abebe EC, Birhan B and Assefa Y (2022) Knowledge, attitude, and intention to accept COVID-19 vaccine among patients with chronic diseases in southern Ethiopia: Multi-center study. *Front. Public Health* 10:917925. doi: 10.3389/fpubh.2022.917925

#### COPYRIGHT

© 2022 Adella Abebe Atnafu Azeze Alene, Molla, Ambaw, Amera, Yosef, Eshetu, Yeshambel, Nigatu, Abebe, Birhan and Assefa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

### Knowledge, attitude, and intention to accept COVID-19 vaccine among patients with chronic diseases in southern Ethiopia: Multi-center study

Getachew Asmare Adella<sup>1\*</sup>, Kelemu Abebe<sup>2</sup>, Natnael Atnafu<sup>2</sup>, Gedion Asnake Azeze<sup>2</sup>, Tamiru Alene<sup>3</sup>, Simegn Molla<sup>1</sup>, Gizachew Ambaw<sup>1</sup>, Tekalign Amera<sup>4</sup>, Amanuel Yosef<sup>1</sup>, Kirubel Eshetu<sup>5</sup>, Adisu Yeshambel<sup>2</sup>, Dabere Nigatu<sup>6</sup>, Endeshaw Chekol Abebe<sup>7</sup>, Belete Birhan<sup>5</sup> and Yibeltal Assefa<sup>1</sup>

<sup>1</sup>School of Public Health, College of Health Science and Medicine, Wolaita Sodo University, Sodo, Ethiopia, <sup>2</sup>School of Midwifery, College of Health Science and Medicine, Wolaita Sodo University, Sodo, Ethiopia, <sup>3</sup>Department of Nursing, College of Health Science, Injibara University, Injibara, Ethiopia, <sup>4</sup>Department of Adult Health Nursing, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia, <sup>5</sup>School of Nursing, College of Health Science and Medicine, Wolaita Sodo University, Sodo, Ethiopia, <sup>6</sup>School of Public Health, College of Health Science and Medicine, Bahir Dar University, Bahir Dar, Ethiopia, <sup>7</sup>Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia

**Background:** Most of the COVID-19 fatal cases and severe illnesses like acute respiratory distress syndrome occur in older adults and other people who have underlying medical comorbidities. Understanding patients with chronic disease' knowledge, attitudes, and intention to take the COVID-19 vaccine and related factors are necessary to control the mortality of COVID-19 infection. Therefore, this study aimed to assess knowledge, attitudes, and intention to take the COVID-19 vaccine among patients with chronic disease in Southern Ethiopia.

**Methods and materials:** A facility-based cross-sectional study was conducted among 409 patients with chronic diseases having a follow-up at the hospitals of the Southern region of Ethiopia from November 14, 2021, to December 24, 2021. A structured, interviewer-administered questionnaire was used to collect data. Bivariate and multivariable logistic regression was conducted to show the association of variables with knowledge, attitude, and intention to take the COVID-19 vaccine. The associations of variables were declared with the use of a 95% CI and *P*-value < 0.05.

**Results:** Overall, 79.2, 70.9, and 58.2% of participants had good knowledge, favorable attitude, and intent to take the COVID-19 vaccine, respectively. Age  $\geq$ 49 years old (AOR = 1.643; 95% CI = 1.008–3.060) and college and above level of education (AOR = 3.002; 95% CI = 1.897–5.021) were found to be significantly associated with knowledge about COVID-19 vaccine. College and above level of education (AOR = 1.510; 95% CI = 1.002–3.975) and good knowledge (AOR = 3.560; 95% CI = 1.481–6.120) were found to be significantly associated with intention to take COVID-19 vaccine.

**Conclusion and recommendation:** Intention to take the COVID-19 vaccine was low among patients with chronic diseases to achieve herd immunity. Therefore, a holistic and multi-sectoral partnership is necessary for a successful COVID-19 vaccination campaign. Further health education and communication are very crucial methods to improve vaccine acceptance and lastly to achieve herd immunity.

KEYWORDS

COVID-19 vaccine, knowledge, attitude, intention, chronic disease

### Introduction

Most of the fatal cases and severe illnesses like acute respiratory distress syndrome (ARDS) occur in older adults and other people who have underlying medical comorbidities like diabetes, cancer, hypertension, heart, lung, and kidney diseases (1-3). The impacts of COVID-19 on patients with chronic disease are not only restricted to direct effects but also in an indirect manner. Resources at all levels have been shifted away from patients with chronic disease management and prevention to pandemic management particularly, in low and middle-income countries, including Ethiopia (4).

African healthcare systems are not well-equipped to tackle this pandemic (5). Since African nations are more vulnerable to disease spread due to limited health infrastructure and training, their inability to obtain the vaccine easily increased the risk of disease spread. However, many developed countries ordered most of the vaccine supplies, but vaccine-related costs and transfer issues can also further delay vaccination procedures for African people as far as late 2021 or early 2022 (6).

At least seven separate vaccines across three channels are administered in countries as of February 18, 2021. Vaccination is prioritized for vulnerable groups in all countries. Simultaneously, more than 200 additional vaccine candidates are being developed, with more than 60 of them in clinical trials (7). Ethiopia received 2.184 million doses of the COVID-19 vaccine on March 7, 2021 (8). Public media sources recently revealed that about 1.9 million people in Ethiopia received their first dose of a COVID-19 vaccine (9).

Based on prior studies, knowledge about the COVID-19 vaccine was in the range of 35.5%-91.15% (10-17), and intention to take the vaccine was within the range of 31.4-64.9% (18-25).

According to studies conducted in various countries around the world, age, occupational status, educational status, income, perceived risk of COVID-19 infection, attitude, knowledge of COVID-19, being sick with COVID-19, and the presence of chronic disease are the most important predictors of intention to use COVID-19 vaccine (10, 26, 27).

There is no study done so far on knowledge, attitude, and intention to take the COVID-19 vaccine among patients with chronic disease in Ethiopia. Therefore, this study aimed to assess knowledge, attitude, and intention to take the COVID-19 vaccine among chronic disease patients in Southwest Ethiopia.

#### Methods and materials

## Study design, setting, period, and population

An institutional-based cross-sectional study was conducted from November 14, 2021, to December 24, 2021, in Wolaita zone hospitals, southern Ethiopia. Wolaita zone is located 328 km south of the capital city Addis Ababa. Based on the 2007 census conducted by the Central Statistical Agency (CSA), the population of the Wolaita zone was projected to be 1,901,112. Wolaita zone is administratively divided into sixteen districts and six town administrations. Currently, there are 9 hospitals and 68 health centers. Those nine hospitals serve as the major referral and reference hospitals in the Woliata zone. The names of the hospitals with their respective total number of patients with chronic diseases attending for follow-up service in 2021 are illustrated as follows: Gesuba Primary Hospital (412), Boditi Primary Hospital (128), Bitena Primary Hospital (316), Halale Primary Hospital (169), Belle Primary Hospital (368), WSUTRH (923), Bombe Primary Hospital (241), Christian Hospital (188), and Dubo Hospital (220). All patients with the chronic disease having a follow-up at the hospitals during the study period were included, whereas patients with chronic diseases who were unable to respond during data collection, <18 years, and health

Abbreviations: ARDS, acute respiratory distress syndrome; AOR, adjusted odds ratio; Cl, confidence interval; COVID-19, corona virus disease–19; ICU, intensive care unit; SD, standard deviation; VIF, variance inflation factor; WSUTRH, woliata sodo university teaching and referral hospital.

professionals were excluded from this study (Wolaita Zone Health Department Annual Report, 2021).

#### Sample size and sampling procedure

The required sample size was calculated by using a single population proportion formula  $[n = Z^2 p (1-p)/d^2]$ with an assumption of 95% confidence interval (CI), 5% margin of error, 50% proportion of knowledge, attitude, and intention to take COVID-19 vaccine among patients with chronic diseases (because there is no study done so far). The sample size was found to be 384. Finally, by adding a 10% non-response rate, the final sample size was 422. Based on the number of patients with chronic diseases follow-up in the hospitals, staffing with internist/GP, and availability of diagnostic materials, five hospitals were selected for study (Gesuba Primary Hospital, Bitena Primary Hospital, Belle Primary Hospital, WSUTRH, Bombe Primary Hospital). According to the report obtained from registration records, at the time of the study, about 2,965 patients with chronic diseases different cases were registered for follow-up in the total selected hospitals. Of the 2,965 patients with chronic diseases on follow-up, 590 were scheduled to present for care or pharmacy pick-ups between November 14, 2021 and December 24, 2021, in selected hospitals, and the samples were allocated proportionally to each selected hospital. Participants who fulfilled the inclusion criteria were offered to participate. A systematic random sampling method was conducted to select the study participants.

# Data collection tools, procedures, measurements, and quality control

A structured interviewer-administered questionnaire was used for data collection. The questionnaire was adopted and modified from different works of literature (10, 13, 17, 28-30). Before distribution, its validity was checked by a panel of experts in the field, and ascertained its content validity. A pretest was also done among 5% of the sample size in Dubo hospital. It was then amended according to the comments raised by the experts and the pretest result. Reliability analysis was done and Cronbach's Alpha had been 0.79, indicating good internal consistency in the responses. It was prepared in the English language, then translated to a local language, and translated back to English to maintain its consistency. The questionnaire had four parts. The first part comprised questions regarding personal socio-demographic information, the second part consisted of knowledge-related items, the third part covered attitude-related items and the last part was intention-related variables. Five diploma nurse data collectors and one-degree nurse supervisors were assigned. The training was given to data collectors and

supervisors for 2 days on the way of administering and gathering the questionnaire. The completeness of the questionnaire was also checked before data entry.

Comprehensive knowledge of the COVID-19 vaccine was computed by summing up all relevant nine knowledge-related questions. The correct answer for each item was scored "1" and the incorrect or do not know the answer was scored "0." Accordingly, respondents who scored greater than or equal to the mean value of the sum of items were thought of as having good knowledge, and respondents who answered less than the mean of the sum of items were thought of as having poor knowledge (13, 30, 31).

The question regarding attitude was six (with a minimum score of six and a maximum score of 30). Five points Likert scale, during which a score of 1-5 was given from strongly disagree to strongly agree supported the score of the attitude. Accordingly, respondents who scored greater than or equal to the mean of the sum of attitude-related questions were thought of as having a favorable attitude, and respondents who answered less than the mean value of the sum of attitude-related questions were thought of as having an unfavorable attitude (13, 29–31).

#### Data processing and analysis

The collected data were coded and entered into Epi Data version 3.1 and then exported to SPSS version 23.0 for analysis. Descriptive statistics were done by computing summary statistics like frequency, mean, percentages, and standard deviation, then the results were presented in tables and graphs. Binary logistic regression was done to assess the association between the dependent and the independent variables. Multivariable logistic regression was applied to ascertain the independent effect of every variable on the dependent variable. Multi-collinearity among the independent variables was checked using VIF (2.14) and Hosmer and Lemeshow test was done to assess model goodness of fit (0.89). The final results of the association were presented based on the AOR at a 95% CI level and p < 0.05.

# Ethical approval and consent from the participant

Ethical approval was obtained from the Institutional Review Board (IRB) of Wolaita Sodo University. A permission letter was obtained from the Woliata Zone Health Department. The consent form was read to the participants and written consent was obtained from each participant before the interview. Participants were informed as they can skip question/s that they don't want to answer partially or fully and to stop at any time if they want to do so. Confidentiality of the individual information was assured by not recording the identifying information.

### **Results**

# Socio-demographic and clinical characteristics of respondents

A total of 409 participants participated in this study with a response rate of 97%. The mean age of the participants was 52.78  $\pm$  (14.69) years old. The majority of the participants 253 (61.9%) were males. The majority of 334 (81.7%) of the participants lived in the urban area. Regarding educational status, 118 (28.9%), and 174 (42.5%) of the participants were in college and above level and secondary educational status, respectively. Concerning the clinical background, 120 (29.3%), and 104 (25.4%) participants had hypertension and Diabetes mellitus, respectively (Table 1).

# Sources of information and knowledge about COVID-19 vaccines

Three hundred forty-nine (85.3%) of participants ever heard about the COVID-19 vaccine. The major sources of information were from national TV/radio (64.7%) and health providers (15.2%). Overall, 324 (79.2%) participants had good knowledge about COVID-19 vaccines (Table 2).

### Factors associated with knowledge about the COVID-19 vaccine among patients with chronic diseases

Age  $\geq$ 49 and educational status were found to be significantly associated with knowledge about the COVID-19 vaccine at a *p* < 0.05. Study participants whose ages  $\geq$ 49 years old were 1.6 times more likely to have good knowledge about the COVID-19 vaccine compared with the age group of 18–34 years (AOR = 1.643; 95% CI = 1.008–3.060). Study participants who had a college and above level of education were three times more likely to have good knowledge about the COVID-19 vaccine compared with those primary level of education (AOR = 3.002; 95% CI = 1.897–5.021) (Table 3).

### Attitude toward COVID-19 vaccine among patients with chronic diseases

Overall, two hundred ninety (70.9%) participants had a favorable attitude toward COVID-19 vaccines whereas 119 (29.1%) of them had an unfavorable attitude toward the COVID-19 vaccine among patients with chronic diseases.

TABLE 1 Sociodemographic and clinical characteristics of patients with chronic diseases, southern Ethiopia, 2021 (N = 409).

Variables	Category	Frequency	Percen
Age	18-34	40	9.8%
	34-49	176	43%
	$\geq 49$	193	47.2%
Sex	Male	253	61.9%
	Female	156	38.1%
Marital status	Married	200	48.9%
	Single	35	8.6%
	Divorced	77	18.8%
	Widowed	97	32.7%
Residence	Urban	334	81.7%
	Rural	75	18.3%
Educational status	Primary education (grade 1–8)	117	28.6%
	Secondary education (grade 9–12)	174	42.5%
	College and above level of education	118	28.9%
Monthly income in USD	<\$40	153	37.4%
	\$40-\$80	84	20.5%
	$\geq \$80$	172	42.1%
Occupation	Merchant	113	27.6%
-	Government employee	127	31.1%
	Private employee	58	14.2%
	Farmer	39	9.5%
	Housewife	37	9.0%
	Others	35	8.6%
Type of chronic diseases	Diabetes mellitus	104	25.4%
	Hypertension	120	29.3%
	Heart diseases	39	9.5%
	Lung diseases	52	12.7%
	DM and hypertension	73	17.8%
	Others	21	5.1%

# Intention to take COVID 19 vaccine among patients with chronic diseases

Two hundred thirty-eight (58.2%) of participants intended to take the COVID-19 vaccine. However, 171 (41.8%) of respondents were not intended to take the COVID-19 vaccine.

Ker heard about COVID 19 vaccine         Yes         349         85.3%           No         60         14.7%           source of information         From news from national TV/radio         226         64.7%           Form government agencies         23         6.6%         5ccial media (Facebook, telegram         29         8.3%           Discusion amongst firend and fimilies         18         5.2%         Halth Care providers         53         15.2%           COVID 19 vaccines use inactivated         Correct         332         81.2%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         600         12.5%         12.5%         600         12.5%         12.5%         600         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12.5%         12	Variables	Category	Frequency	Percent
And ControlAnd ActionFrom gover from national TV/radio266.4%Social media (Facebook, telegran296.6%Social media (Facebook, telegran298.2%Decisiona anongoti frends and families185.2%COVID 10 socines use inactivatedCorrect3018.2%COVID 10 socines anongoti frends and families167.7%18.8%COVID 10 socines use inactivatedCorrect718.8%COVID 10 socines use genetic materialCorrect3157.7%From gover national formation718.8%2.5%COVID 10 socines use genetic materialCorrect297.21%From gover national formation142.7%2.5%COVID 10 socines sole genetic materialCorrect317.7%From gover national formation142.7%2.5%COVID 10 socines will be given viaCorrect2.97.2%Corregdo not know122.1%7.2%Corregdo not know2.27.2%7.2%Covid Di socines will be given viaCorrect2.97.2%Covid Di socines will be given viaCorrect3.1%7.3%Covid Di socines will be given viaCorrect3	Ever heard about COVID 19 vaccine	Yes	349	85.3%
Form government agencies36.8%Nord mecha (accebook, degram298.3%Discissi namopat frieds and families365.2%COVD19 vaccines une inactivatedCorrect328.2%coronavirus at heat igent328.2%COVD19 vaccines une inactivatedCorrect328.2%COVD19 vaccines une inactivatedCorrect328.2%COVD19 vaccines une inactivatedCorrect378.2%COVD-19 vaccines une agenci ten also protect usCorrect378.2%COVD-19 vaccines une gence in also protect usCorrect328.2%COVD-19 vaccines use gence in and use in also protect usCorrect328.2%COVD-19 vaccines use gence in also protect usCorrect328.2%COVD-19 vaccines use protect usCorrect328.2%COVD-19 vaccines une protect usCorrect328.2%COVD-19 vaccines une protect usCorrect328.2%COVD-19 vaccines une protect usCorrect329.2%COVD-19 vaccines une protect usCorrect329.2%COVD-19 vaccines une protect usCorrect329.2%COVD-19 vaccines une pr		No	60	14.7%
Social media (Facebook delgram)298.3%Discussion anonget friends and families185.2%Bith are providers1315.3%COVD 19 vaccines use inactivatedOrrect1318.8%COVD 19 vaccines use protect us0.0rect1318.8%COVD-19 vaccines use protect us0.0rect1318.8%COVD-19 vaccines use genetic material0.0rect1327.8%COVD-19 vaccines use genetic material0.0rect1327.8%COVD-19 vaccines use genetic material0.0rect1328.8%COVD-19 vaccines use genetic material0.0rect1328.8%COVD 19 vaccination0.0rect290.0%COVD 19 vaccination0.0rect290.0%COVD-19 vaccination0.0rect290.0%COVD-19 vaccination may protect0.0rect290.8%COVD-19 vaccination may protect0.0rect200.8%COVD-19 vaccination may protect0.0rect200.8%COVD-19 vaccination may protect0.0rect130.0%COVD-19 vaccination terve terve0.0rect0.0rect0.0rectCOVD-19 vaccination terve terve0.0rect0.0rect0.0rectCOVD-19 vaccination terve terve0.0rect0.0rect0.0rect <tr< td=""><td>source of information</td><td>From news from national TV/radio</td><td>226</td><td>64.7%</td></tr<>	source of information	From news from national TV/radio	226	64.7%
Discussion amongst friends and families185.2%COVID 19 vaccines use inactivatedCorrect3.315.2%COVID 19 vaccines use inactivatedCorrect3.315.2%COVID -19 vaccine as use particeKorred3.157.7%COVID -19 vaccine as use particeCorrect3.157.7%COVID -19 vaccine as use partice materialCorrect3.157.7%COVID -19 vaccines use genetic materialCorrect2.957.21%CorrectCorrect2.957.21%CorrectCorrect2.957.21%CorrectCorrect2.957.21%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.778.24%CorrectCorrect3.783.78CorrectCorrect3.793.78CorrectCorrect3.793.78CorrectCorrect3.793.78CorrectCorrect3.793.78CorrectCorrect3.783.78CorrectCorrect3.793.78CorrectCorrect3.793.78CorrectCorrect <td></td> <td>From government agencies</td> <td>23</td> <td>6.6%</td>		From government agencies	23	6.6%
Halh car providers5315.2%COVDI J9 vaccines use inactivatedCorrect33.28.2%corours as the antigers"Mongdo not now78.2%COVDI-J9 vaccine can also protect usGarcet31.57.7%from influenzaToret3.27.2%COVDI-J9 vaccine use genet for not now102.5%7.2%COVDI-J9 vaccine use genet for not now102.5%7.2%COVDI-J9 vaccine use genet for not now102.5%7.2%COVDI-J9 vaccine use genet for not now102.5%7.5%COVID-J9 vaccine use genet for not now102.5%7.5%Coving Jane La Coving Jane La Co		Social media (Facebook, telegram	29	8.3%
COVID 19 vaccines use inactivated coronavirus as the antigen"3328.12%COVID-19 vaccine analso protects form influenza7018.8%COVID-19 vaccines use genetic material form coronavirus as the active form coronavirus as the active difference form correct coronavirus coronavirus as the active difference form correct coronavirus coronavirus coronavirus coronavirus coronavirus correct coronavirus correct coronavirus coronavirus coronavirus coronavirus correct		Discussion amongst friends and families	18	5.2%
convarius as the antigentYeng/do not know718.8%COVID-19 vaccine can also protect us from influenzaOrect718.9%COVID-19 vaccines use genetic material convarius as the active influenceOrect20572.1%COVID-19 vaccines use genetic material convarius as the active influenceOrect20572.1%COVID-19 vaccines use genetic material convarius as the active influenceMangdo not know942%COVID-19 vaccines will be given via injection*Orect3762.4%COVID-19 vaccines will be given via injection*Orect3772.6%COVID-19 vaccines will be given via injection*Orect3728.2%COVID-19 vaccination conventueOrect3636.4%COVID-19 vaccination may protect to pole who do not receive the uscretOrect3636.4%COVID-19 vaccination may protect to corectOrect3236.1%COVID-19 vaccination may protect to corectOrect3236.1%COVID-19 vaccination may protect to corectOrect3236.1%COVID-19 vaccination the side to corectOrect3736.1%COVID-19 vaccination the side to corectOrect3736.1%COVID-19 vaccination the side to corectOrect3636.1%COVID-19 vaccination the side to corectOrect3736.1%COVID-19 vaccination the side to corectOrect3636.1%COVID-19 vaccination the side to corect <td< td=""><td></td><td>Health care providers</td><td>53</td><td>15.2%</td></td<>		Health care providers	53	15.2%
Normal StateWring/do not know718.88COVID-19 vaccine can also protect usCorrect31577%from influenzaWrong/do not know9492%COVID-19 vaccines use genetic materialCorrect21%72%from coronavirus as the activeNored1472%greedent*Vorted32%72%COVID 19 vaccines will be given viaCorrect1472%Norng/do not know717.6%COVID-19 vaccines will be given viaCorrect28%70.7injection*Wrong/do not know7217.6%CovID-19 vaccinationCorrect28%70.7COVID-19 vaccinationCorrect28%70.7CoVID-19 vaccinationCorrect28%70.7CoVID-19 vaccination may protectCorrect28%70.7CoVID-19 vaccination may protectCorrect31651.6%CoVID-19 vaccine protects the receiver theCorrect3176%CoVID-19 vaccine protects the receiver theCorrect31176%CoVID-19 vaccine protects the receiver theCorrect31176% <td>COVID 19 vaccines use inactivated</td> <td>Correct</td> <td>332</td> <td>81.2%</td>	COVID 19 vaccines use inactivated	Correct	332	81.2%
OVID-19 vacine can also protect usOrect31577%from influenzaWrong/do not know9429%COVID-19 vacines segnetic materialCorrect29572.18from coronavirus as the activeWrong/do not know1427.9%COVID 19 vacines will be given viaCorrect3782.48ingredient"Wrong/do not know1427.9%COVID 19 vacines will be given viaCorrect3782.48ingredient"Wrong/do not know77.6%Everyone including children can receiveCorrect28970.76COVID-19 vaccination77.6%3.5%COVID-19 vaccination may protectCorrect363.6%Covid L9 vaccination may protectCorrect363.6%COVID-19 vaccination may protectCorrect313.6%COVID-19 vaccination may protectCorrect313.6%Covid L9 vaccination may protectCorrect313.6%Covid L9 vaccination may protectCorrect313.6%Covid L9 vaccine stom teresive theCorrect313.6%Covid L9 vaccine stom teresive theCorrect313.6%Covid L9 vaccine stom teresiveCorrect313.6%Covid L9 vaccine stom teresiveCorrect313.6%Covid L9 vaccine stom teresiveCorrect313.6%Covid L9 vaccine stom teresiveCorrect3.6%3.6%Covid L9 vaccine stom teresiveCorrect3.6%3.6	coronavirus as the antigen*			
fm influenza         9         23%           COVID-19 vaccines use genetic material         Corect         25         2.1%           form coronavirus as the active         1         2.5%         2.1%           incoronavirus as the active         1         2.5%         2.1%           incoronavirus as the active         1         2.5%         2.5%           incert         1         2.5%         2.5%           COVID 19 vaccines will be given via         Correct         3.37         2.82%           COVID 19 vaccination         1         2.5%         2.6%           Cover on including children can receive         Correct         2.6%         2.6%         2.6%           CoVID 19 vaccination         2         7.6%         2.6		Wrong/do not know	77	18.8%
Nong/do not know9429%COVID-19 vaccines use genetic materialCorrect2572.1%ingredient*Nong/do not know1427.9%COVID-19 vaccines will be given viaCorrect3782.8%ingerionNong/do not know7217.6%CovID-19 vaccines will be given viaCorrect28970.7Keryone including children can receiveCorrect28970.7CoVID-19 vaccinationNong/do not know7217.6%CoVID-19 vaccinationCorrect3684.6%CoVID-19 vaccination may protectCorrect3636.4%CoVID-19 vaccination may protectCorrect3636.4%CoVID-19 vaccination may protectCorrect3286.1%CoVID-19 vaccination may protectCorrect3286.1%CoVID-19 vaccination may protectCorrect3286.1%CoVID-19 vaccination may protectCorrect3286.1%CoVID-19 vaccination may protectCorrect3176%CoVID-19 vaccination may protectCorrect3176%CoVID-19 vaccination may protectCorrect3424%CoVID-19 vaccination may protectCorrect3424%CoVID-19 vaccination may existCorrect3424%CoVID-19 vaccination correctSingle Correct3424%CoVID-19 vaccination correctSingle Correct3424%CoVID-19 vaccination correctSingle Correct3434%CoVI	COVID-19 vaccine can also protect us	Correct	315	77%
CVUD-19 vaccines use genetic materialOr29521,2%from coronavirus as the activeinterestinterestinterestingredient*11427,9%COUD 19 vaccines will be given viaCorect3062,4%injection*Vong/do not know7217,6%Everyone including children can receiveCorrect28970,7COUD-19 vaccinationCorect28970,7%COUD-19 vaccination may protectCorrect28029,3%COUD-19 vaccination may protectCorrect3684,6%other pole who do not receive theVong/do not know3015,4%COUD-19 vaccination may protectCorrect3286,1%CorrectVong/do not know5713,9%COUD-19 vaccine protects the receiverCorrect317,6%CorrectSorrect312,6%CorrectSorrect312,6%CorrectSorrect312,6%CorrectSorrect312,6%CorrectSorrect322,6%CorrectSorrect322,6%CorrectSorrect332,6%CorrectSorrect332,6%CorrectSorrect332,6%CorrectSorrect332,6%CorrectSorrect332,6%CorrectSorrect332,6%CorrectSorrect332,6%CorrectSorrect332,6% <td>from influenza</td> <td></td> <td></td> <td></td>	from influenza			
from coronavirus as the active       ingredient*         ingredient*       114       27.9%         COVID 19 vaccines will be given via       6 crect       337       8.24.4%         injection*       10       37       8.24.4%         injection*       70       17.4%       8.24.4%         Coving 19 vaccines will be given via       6 crect       20       7.6%         Coving 10 conductor       70       20.3%       7.6%         Coving 10 conductor       70       7.6%       7.6%         Coving 10 conductor       7.6%       7.6%       7.6%         Coving 10 conductor       7.6%       7.6%       7.6%       7.6%         Coving 10 conductor       7.6%       7.6%       7.6%       7.6		Wrong/do not know	94	23%
ingredient*Knog/do not know11427.9%CVDD 19 vaccines will be given via injection*Greect33782.4%Knog/do not know7217.6%Everyone including children can receive commerciants26970.70CVDD-19 vaccination7229.3%CVDD-19 vaccination1029.3%CVDD-19 vaccination may protectGreect20CVDD-19 vaccination may protectGreect36226.3%CVDD-19 vaccination may protectGreect35286.1%CVDD-19 vaccination may protectGreect35286.1%CVDD-19 vaccine protects the receiver for utilized for the commerciant set to the c	COVID-19 vaccines use genetic material	Correct	295	72.1%
number of the second	from coronavirus as the active			
COVID 19 vaccines will be given via         For         337         82.4%           injection*         Wrong/do not know         72         17.6%           Everyone including children can receive         Correct         289         70.7           COVID-19 vaccination         120         29.3%           COVID-19 vaccination may protect         Correct         36         84.6%           other people who do not receive the         Vorg/do not know         120         29.3%           COVID-19 vaccination may protect         Correct         36         84.6%           other people who do not receive the         Vorg/do not know         120         29.3%           COVID-19 vaccination may protect         Grong/do not know         63         15.4%           COVID-19 vaccine sterceiver         Krong/do not know         63         15.4%           COVID-19 vaccines do not have side         Correct         311         37.5%           COVID-19 vaccines do not have side         Correct         313         28.4%           COVID-19 vaccine stimulates our body         Correct         339         82.4%           COVID-19 vaccine stimulates our body         Correct         339         82.4%           COVID-19 vaccine stimulates our body         Correct         339	ingredient*			
injection*         72         17.6%           Korego on know         29         70.7           COVID-19 vaccination         20         29.3%           COVID-19 vaccination         120         29.3%           COVID-19 vaccination may protect         Corect         36.6         84.6%           Other people who do not receive the         Ving/do not know         36.6         84.6%           Other people who do not receive the         Ving/do not know         63         15.4%           COVID-19 vaccine protects the receiver         Corect         32         86.1%           COVID-19 vaccine protects the receiver         Corect         32         86.1%           form getting COVID-19 infection*         Ving/do not know         63         15.4%           COVID-19 vaccines do not have side         Corect         31         76%           effets         Ving/do not know         63         24%           COVID-19 vaccine stimulates our body         Corect         31         76%           COVID-19 vaccine stimulates our body         Corect         32         82.9%           Covido ta stimulates our body         Corect         32         82.9%           Covido ta stimulates our body         Corect         32         82.9%		Wrong/do not know	114	27.9%
Yeng/do not know         72         17.6%           Everyone including children can receive         Correct         289         70.7           COVID-19 vaccination         120         29.3%           COVID-19 vaccination may protect         Correct         346         84.6%           COVID-19 vaccination may protect         Correct         346         84.6%           other people who do not receive the	COVID 19 vaccines will be given via	Correct	337	82.4%
Persone including children can receive         Orrect         289         70.7           COVID-19 vaccination         Wrong/do not know         120         29.3%           COVID-19 vaccination may protect         Gorrect         346         84.6%           other people who do not receive the          70.7         70.7           vaccine*          70.7         70.7           COVID-19 vaccination may protect         Gorrect         70.7         70.7           vaccine*          70.7         70.7           COVID-19 vaccine protects the receiver         Gorrect         70.7         70.7           from getting COVID-19 infection*          70.7         71.9%           COVID-19 vaccine do not have side         Gorrect         70.7         71.9%           GOVID-19 vaccine do not have side         Correct         71.7%         76%           effects          71.7%         72.4%           COVID-19 vaccine stimulates our body         Correct         32.9         24%           COVID-19 vaccine stimulates our body         Correct         33.9         24%           Covide antibudies*          71.7         71.7%	injection*			
NOVID-19 vaccination       I20       29.3%         COVID-19 vaccination may protect       Correct       346       84.6%         other people who do not receive the       346       84.6%         vaccine*       Vong/do not know       63       15.4%         COVID-19 vaccine the receiver       Gorrect       63       15.4%         COVID-19 vaccine protects the receiver       Gorrect       352       86.6%         COVID-19 vaccine store the receiver       Gorrect       13.9%       13.9%         COVID-19 vaccines do not have side       Gorrect       57       13.9%         COVID-19 vaccine store there et with the store of		Wrong/do not know	72	17.6%
Nong/do not know12029.3%COVID-19 vaccination may protectCorrect34684.6%other people who do not receive thevaccine*Nong/do not know6315.4%COVID-19 vaccine protects the receiverCorrect35286.1%form getting COVID-19 infection*7713.9%COVID-19 vaccines do not have sideCorrect5713.9%COVID-19 vaccines do not have sideCorrect31176%COVID-19 vaccines do not have sideCorrect33924%COVID-19 vaccines do not have sideCorrect33924%COVID-19 vaccines do not have sideCorrect31075%COVID-19 vaccines do not have sideCorrect33924%COVID-19 vaccines do not have sideCorrect33932%COVID-19 vaccines do not have sideCorrectCorrectCorrectCOVID-19 vaccines do not have sideCorrect33932%Covide antibodies*CorrectCorrectCorrectCorrectCovide antibolies*CorrectCorrectCorrectCorrectCovide ge about vaccineCovide correctCorrectCorrectCorrectCovide ge about vaccineCovide correctCorrectCorrectCorrectCovide ge about vaccineCovide correctCovide correctCovide correctCovide correctCovide ge about vaccineCovide correctCovide correctCovide correctCovide correctCovide correct <td>Everyone including children can receive</td> <td>Correct</td> <td>289</td> <td>70.7</td>	Everyone including children can receive	Correct	289	70.7
COVID-19 vaccination may protectCorrectSelectSelectvaccine*Wrong/do not know6315.4%COVID-19 vaccine protects the receiver form getting COVID-19 infection*Correct35286.1%Wrong/do not know5713.9%COVID-19 vaccines do not have side effectsCorrect31176%COVID-19 vaccines do not have side effectsMong/do not know9824%COVID-19 vaccine simulates our body to rectCorrect31924%COVID-19 vaccine simulates our body to rectGorect31924%Covide antibodies*Wrong/do not know9824%Covide antibodies*Wrong/do not know7017.1%Knowledge about vaccineGod32479.2%	COVID-19 vaccination			
other people who do not receive the vaccine* IVrong/do not know Go Tect Correct Correc		Wrong/do not know	120	29.3%
vacine*           vacine         Mrong/do not know         63         15.4%           COVID-19 vaccine protects the receiver         Correct         352         86.1%           from getting COVID-19 infection*         Mrong/do not know         57         13.9%           COVID-19 vaccines do not have side         Correct         311         76%           effects         Mrong/do not know         98         24%           COVID-19 vaccine stimulates our body         Correct         339         82.9%           COVID-19 vaccine stimulates our body         Correct         339         82.9%           to produce antibodies*         Mrong/do not know         70         17.1%           Knowledge about vaccine         God         324         79.2%	COVID-19 vaccination may protect	Correct	346	84.6%
Wrong/do not know6315.4%COVID-19 vaccine protects the receiver from getting COVID-19 infection*5286.1%Wrong/do not know5713.9%COVID-19 vaccines do not have side effectsCorrect31176%Mrong/do not know9824%COVID-19 vaccine stimulates our body to produce antibodies*Correct33982.9%Mrong/do not know7017.1%Knowledge about vaccine5479.2%	other people who do not receive the			
COVID-19 vaccine protects the receiver from getting COVID-19 infection*35286.1%Wrong/do not know5713.9%COVID-19 vaccines do not have side effectsCorrect31176%Wrong/do not know9824%COVID-19 vaccine stimulates our body to produce antibodies*Correct33982.9%Knowledge about vaccine60d7017.1%	vaccine*			
from getting COVID-19 infection*       Wrong/do not know     57     13.9%       COVID-19 vaccines do not have side     Correct     311     76%       effects     Wrong/do not know     98     24%       COVID-19 vaccine stimulates our body     Correct     339     82.9%       Corroduce antibodies*     Wrong/do not know     70     17.1%       Knowledge about vaccine     God     324     79.2%		Wrong/do not know	63	15.4%
Nong/do not know5713.9%COVID-19 vaccines do not have sideCorrect31176%effectsWrong/do not know9824%COVID-19 vaccine stimulates our bodyCorrect33982.9%COVID-19 vaccine stimulates our bodyCorrect33982.9%to produce antibodies*Nong/do not know7017.1%Knowledge about vaccineGod32479.2%	COVID-19 vaccine protects the receiver	Correct	352	86.1%
COVID-19 vaccines do not have sideCorrect31176%effectsWrong/do not know9824%COVID-19 vaccine stimulates our bodyCorrect33982.9%COVID-19 vaccine stimulates our bodyCorrect33982.9%to produce antibodies*Vrong/do not know7017.1%Knowledge about vaccineGod32479.2%	from getting COVID-19 infection*			
effects		Wrong/do not know	57	13.9%
Wrong/do not know9824%COVID-19 vaccine stimulates our body to produce antibodies*30982.9%Wrong/do not know7017.1%Knowledge about vaccine5032479.2%	COVID-19 vaccines do not have side	Correct	311	76%
COVID-19 vaccine stimulates our bodyCorrect33982.9%to produce antibodies*Wrong/do not know7017.1%Knowledge about vaccineGood32479.2%	effects			
to produce antibodies* Vrong/do not know 70 17.1% Knowledge about vaccine Good 324 79.2%		Wrong/do not know	98	24%
Wrong/do not know         70         17.1%           Knowledge about vaccine         God         324         79.2%	COVID-19 vaccine stimulates our body	Correct	339	82.9%
Knowledge about vaccineGood32479.2%	to produce antibodies*			
		Wrong/do not know	70	17.1%
Poor 85 20.8%	Knowledge about vaccine	Good	324	79.2%
		Poor	85	20.8%

TABLE 2 Source of information and knowledge about COVID-19 vaccine among patients with chronic diseases, southern Ethiopia, 2021 (N = 409).

\*Yes was the correct answer.

# Factors associated to take the COVID-19 vaccine among patients with chronic diseases

Educational status and knowledge were found to be significantly associated with intention to take the COVID-19 vaccine at p < 0.05. Study participants who had a college and

above level of education were 1.5 times more likely to intend to take the COVID-19 vaccine compared with those who had a primary level of education (AOR = 1.510; 95% CI = 1.002-3.975). Study participants who had good knowledge about the COVID-19 vaccine were 3.6 times more likely to intend to take the COVID-19 vaccine compared with their counterparts (AOR = 3.560; 95% CI = 1.481-6.120) (Table 4).

Variables	Knowledge		COR (95% CI)	AOR (95% CI)	P-value
	Good knowledge	Poor knowledge			
Sex					
Male	206 (81.4%)	47 (18.6%)	1.425 (1.043-3.132)	2.001 (0.808-4.005)	0.402
Female	118 (75.6%)	38 (24.4%)	1	1	
Residence					
Urban	275 (82.3%)	59 (17.7%)	2.473 (1.432-4.879)	3.627 (0.750-5.440)	0.330
Rural	49 (65.3%)	26 (34.7%)	1	1	
Age					
18–34	31 (75.5%)	9 (22.5%)	1	1	
34-49	(15,185.8%)	25 (14.2%)	1.753 (0.543–1.781)	2.87 (0.889-4.120)	0.520
$\geq 49$	142 (73.6%)	51 (26.4%)	0.808 (0.401-2.320)	1.643 (1.008-3.060)*	0.004
Educational status					
Primary education (grade 1-8)	96 (82.1%)	21 (17.9%)	1	1	
Secondary education (grade 9-12)	122 (70.1%)	52 (29.9%)	0.513 (0.106–1.110)	1.106 (0.743-2.910)	0.380
College and above	106 (89.8%)	12 (10.2%)	1.932 (1.182–3.880)	3.002 (1.897-5.021)*	0.000

TABLE 3 Factors associated with knowledge about COVID-19 vaccine among patients with chronic diseases, southern Ethiopia, 2021 (N = 409).

\*Statistically significant at p < 0.05. The meaning of bold value was to show they were statistically significant category of the variable. In short to easily catchup the predictor variables.

TABLE 4 Factors associated with intention to take COVID-19 vaccine among patients with chronic diseases, southern Ethiopia, 2021 (N = 409).

Variables	Intended to tak	Intended to take the COVID-19 vaccine		AOR (95% CI)	P-value
	Yes	No			
Age					
18-34	18 (45%)	22 (55%)	1	1	
34-49	116 (65.9%)	60 (34.1%)	2.363 (1.089-4.521)	2.516 (0.944-4.877)	0.630
$\geq 49$	104 (53.9%)	89 (46.1%)	1.428 (0.870-2.867)	2.001 (0.693-3.302)	0.420
Educational status					
Primary education	79 (65.7%)	38 (32.5%)	1	1	
Secondary education	113 (64.9%)	61 (35.1%)	0.891 (0.241-2.003)	1.061 (0.796-2.228)	0.316
College and above	46 (39%)	72 (61%)	0.307 (0.1008-1.841)	1.510 (1.002-3.975)*	0.001
Monthly income in USD					
<\$40	111 (72.5%)	42 (27.5%)	1	1	
\$40-\$80	41 (48.8%)	43 (51.2%)	0.361 (0.064-0.830)	0.419 (0.207-1.954)	0.120
≥\$80	86 (50%)	86 (50%)	0.378 (0.049-0.920)	0.651 (0.104-1.480)	0.09
Knowledge about the vaccine	e				
Good	192 (59.3%)	132 (40.7%)	1.233 (1.009-3.041)	3.560 (1.481-6.120)*	0.000
Poor	46 (54.1%)	39 (45.9%)	1	1	

\*Statistically significant at p < 0.05. The meaning of bold value was to show they were statistically significant category of the variable. In short to easily catchup the predictor variables.

#### Discussions

The COVID-19 pandemic has been a health issue of great concern since its start in 2020 and causes high morbidity and mortality, especially in the higher-risk population groups like the one in this study, patients with chronic diseases (32). Vaccination is not the only, but the best solution to controlling infectious diseases (33). However, while most people vaccinate according to the recommended schedule, success is being challenged by multiple factors, especially in Africa. some of the major challenges threatening the success of the COVID-19 vaccination rollout in most African countries include the slow onset of the vaccination exercise, limited funds, concerns around vaccine safety and uncertainties, storage requirements and regulatory hurdles for vaccines, limited shelf life of COVID-19 vaccines, inability to access vulnerable communities in a timely fashion, problems around the use of different vaccines, and wars and conflicts (34).

In this study, the overall magnitude of knowledge, attitude, and intention to take the COVID-19 vaccine and associated factors among patients with chronic diseases in southern Ethiopia were investigated. Age and educational status were predictor variables for knowledge about the COVID-19 vaccine. Educational status and knowledge were predictor variables for intention to take the COVID-19 vaccine.

In this study, 79.2% (95% CI = 69.3-84.3%) of the participants had good knowledge about COVID 19 vaccine. This study's findings were similar to that of a study conducted in Ethiopia's Gurage Zone (74%) (13). The finding was higher than the studies conducted in West India (35.5%), Illibabur and Bedelle Zones of Ethiopia (64%), Bangladesh (62.1%), Southwest Ethiopia (60.8%), Jordan (50%), and Malaysia (38%) (10, 11, 15, 16, 35, 36). The disparities may be due to differences in the study population. The study population of this study was people who have a chronic medical illness. These individuals have less immunity and they are at risk of contracting communicable diseases including COVID-19 infection. They become more concerned about their health so they may search for different information outlets. The majority (85.3%) of our respondents who ever heard about the COVID-19 vaccine support this. The other reason may be due to differences in educational status. All of our study participants had a primary and above level of education and 71.4% of them had a secondary and above level of education. It may be the case that people that are more educated are more knowledgeable and concerned about their health and wellbeing, through access to more information sources, and become more engaged in life events that could affect them (37).

However, it was lower than studies conducted in Greece (88.28%), Oman (88.4%), and Romania (95.15%) (12, 14, 17). The difference may be due to variations in study participants and socioeconomic status. In a study done in Greece, the study participants were health care workers. Health care workers are more knowledgeable than other professions (16). The above studies were done in economically better counties with a wellintegrated health system than our setup where study participants had family physicians which are unthinkable to our setup. When comparing the age groups of 18-34 years old and 49 years old and above, study participants who were 49 years old and above were 1.6 times more likely to have good knowledge about the COVID-19 vaccine. The findings matched with research from India, Jordan, and Southwest Ethiopia (11, 16, 31, 36). This could be because older people are more likely than younger people to experience serious side effects; as a result, they get concerned and look for additional information about the vaccine.

Study participants who had college and above level of education were three times more likely to have good knowledge about the COVID-19 vaccine compared with those with primary levels of education. This was consistent with studies done in Malaysia, Jordan, Bangladesh, and Southwest Ethiopia (15, 16, 35, 36). It's possible that people with more education are more knowledgeable and worried about their health and wellbeing, and become more active in life events that may affect them (37), such as COVID-19 immunizations because they have access to more information sources.

The overall proportion of favorable attitudes of participants toward the COVID-19 vaccine was 70.9%. This finding was consistent with studies done in Belgium and Italy (17, 27). However, it was higher than studies in Ethiopia (44.7% and 24.2%), UK (36.9%), and Egypt (34.3%) (13, 28, 38, 39). The disparity may be due to differences in features of study participants. Although the proportion of the population that needs to be vaccinated to achieve herd immunity remains largely unknown, some have estimated that the herd immunity threshold for COVID-19 ranges from 60 to 70% (34, 40).

According to the finding of this study, 58.2% (95% CI = 51.0-61.2%) of study participants had intention to take COVID 19 vaccine. This finding was consistent with studies done in Dessie (59.4%), Gondar (54.8%), and the Kingdom of Saudi Arabia (52%) (18, 19, 25). It was lower than the findings of research conducted in Saudi Arabia (64.7%) and Ethiopia (64.9%) (20, 21). The disparities may be because of a difference in study design that is institutionally based in this study whereas web-based national survey in the previous studies. However, it was higher than studies conducted in Butajira (33.7%), Woliata Sodo town (46.1%), and national level Ethiopia (31.4%) (22-24). The difference could be due to the difference in the study population. In this study, the study population was patients with chronic diseases have a high vaccine acceptance rate (41–43).

Study participants who had college and above level of education were 1.5 times more likely to intend to take the COVID-19 vaccine compared with those who had a primary level of education. This finding was supported by studies done in Ethiopia at a national level, Gondar, and the Kingdom of Saudi Arabia (18, 21, 22, 25). This is because education raises public awareness of the vaccine's health benefits. Several studies have found that more years of training are linked to greater acceptance of the COVID-19 vaccination (44, 45).

Study participants who had good knowledge about the COVID-19 vaccine were 3.6 times more likely to intend to take the COVID-19 vaccine compared with their counterparts. This was in line with studies done in Dessie, Butajira, and Ethiopia at the national level (19, 21, 22). This might be because knowing is a prerequisite to developing intention. If participants are aware of the advantages of vaccines through different outlets, this facilitates informed decisions and could be intended to take the vaccine. The effectiveness of vaccines relies on both clinical efficacy and a community's knowledge. During vaccine promotion, lack of community support due to poor knowledge and perceptions resulted in poor community uptake while others reject vaccines (46).

#### 10.3389/fpubh.2022.917925

#### Limitation of study

This study has some limitations. The cross-sectional design of the study inherently limits determining the direction of causation, between dependent and independent variables. Besides, since it was a quantitative approach, it does not explore the participants' deep feelings, acceptability and reason for refusal, or beliefs about the COVID-19 vaccine, unlike a qualitative approach. In addition, there might be a potential for social desirability bias, which means participants may have been inclined to provide socially desirable responses rather than describe actual beliefs and practices.

### **Conclusions and recommendations**

Knowledge and attitudes toward the COVID-19 vaccine among patients with chronic disease were high relative to other studies. However, the intention to take the COVID-19 vaccine was low to achieve herd immunity.

Age and educational status were predictor variables for knowledge about the COVID-19 vaccine. Educational status and knowledge were predictor variables for intention to take the vaccine among patients with chronic diseases.

Holistic and multi-sectoral partnership is necessary for a successful COVID-19 vaccination campaign. Further health education and communication are very crucial methods to improve vaccine acceptance and lastly to achieve herd immunity.

#### Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

#### **Ethics statement**

The studies involving human participants were reviewed and approved by Wolaita Sodo University Institutional Review

#### References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med.* (2020) 382:1199–207. doi: 10.1056/NEJMoa2001316

2. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. (2020) 323:1499–500. doi: 10.1001/jama.2020.3633

3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3

4. Danhieux K, Buffel V, Pairon A, Benkheil A, Remmen R, Wouters E, et al. The impact of COVID-19 on chronic care according to providers: a qualitative Board (IRB). The patients/participants provided their written informed consent to participate in this study.

#### Author contributions

All authors made considerable contributions to conception and design, acquisition of data, or evaluation and interpretation of data, took section in drafting the article or revising it significantly for necessary intellectual content, agreed to put up to the current journal, gave ultimate approval of the version to be published, and agree to be responsible for all elements of the work.

#### Acknowledgments

We are very grateful to the Woliata Sodo University College of Health Science and Medicine for giving us the ethical clearance. We are also indebted to thank study participants for their cooperation during data collection.

### **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

study among primary care practices in Belgium. BMC Fam Pract. (2020) 21:1-6. doi: 10.1186/s12875-020-01326-3

<sup>5.</sup> Elhadi M, Msherghi A, Alkeelani M, Alsuyihili A, Khaled A, Buzreg A, et al. Concerns for low-resource countries, with under-prepared intensive care units, facing the COVID-19 pandemic. *Infect Dis Health.* (2020) 25:227–32. doi: 10.1016/j.idh.2020.05.008

Economist Intelligent Unit. More Than 85 Poor Countries Will Not Have Widespread Access to Coronavirus Vaccines Before 2023. The Economist. (2021). Available online at: https://www.eiu.com/n/85-poor-countries-will-nothave-access-to-coronavirus-vaccines/ (accessed December 18, 2020).

7. World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 Subcommittee on Safety Signals Related to the AstraZeneca COVID-19 Vaccine. Geneva (2021).

8. World Health Organization. 2.2 Million COVID-19 Vaccines Allocated by the COVAX Facility Arrive in Ethiopia, Marking the Start of the Country's COVID-19 Vaccination Campaign. Adis Ababa (2021).

9. Zewude B, Belachew A. Intention to receive the second round of COVID-19 vaccine among healthcare workers in Eastern Ethiopia. *Infect Drug Resist.* (2021) 14:3071. doi: 10.2147/IDR.S326055

10. Bhartiya S, Kumar N, Singh T, Murugan S, Rajavel S, Wadhwani M. Knowledge, attitude and practice towards COVID-19 vaccination acceptance in West India. *Int J Community Med Public Heal.* (2021) 8:1170. doi: 10.18203/2394-6040.ijcmph20215014

11. Ahmed MH, Siraj SS, Klein J, Ali FY, Kanfe SG. Knowledge and attitude towards second COVID-19 vaccine dose among health professionals working at public health facilities in a low income country. *Infect Drug Resist.* (2021) 14:3125. doi: 10.2147/IDR.S327954

12. Papagiannis D, Malli F, Raptis DG, Papathanasiou IV, Fradelos EC, Daniil Z, et al. Assessment of knowledge, attitudes, and practices towards new coronavirus (SARS-CoV-2) of health care professionals in Greece before the outbreak period. *Int J Environ Res Public Health.* (2020) 17:1–14. doi: 10.3390/ijerph17144925

13. Abebe H, Shitu S, Mose A. Understanding of COVID-19 vaccine knowledge, attitude, acceptance, and determinates of COVID-19 vaccine acceptance among adult population in Ethiopia. *Infect Drug Resist.* (2021) 14:2015. doi: 10.2147/IDR.S312116

14. Al-Marshoudi S, Al-Balushi H, Al-Wahaibi A, Al-Khalili S, Al-Maani A, Al-Farsi N, et al. Knowledge, attitudes, and practices (KAP) toward the COVID-19 vaccine in oman: a pre-campaign cross-sectional study. *Vaccines.* (2021) 9:602. doi: 10.3390/vaccines9060602

15. Islam MS, Siddique AB, Akter R, Tasnim R, Sujan MS, Ward PR, et al. Knowledge, attitudes, and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh. *medRxiv.* (2021) 21:1851. doi: 10.1101/2021.02.16.21251802

16. Asmare Adella G. Knowledge and attitude toward the second round of COVID-19 vaccines among teachers working at southern public universities in Ethiopia. *Human Vacc Immunother*. (2022) 18:1–7. doi: 10.1080/21645515.2021.2018895

17. Popa GL, Muntean AA, Muntean MM, Popa MI. Knowledge and attitudes on vaccination in southern romanians: a cross-sectional questionnaire. *Vaccines*. (2020) 8:774. doi: 10.3390/vaccines8040774

18. Handebo S, Wolde M, Shitu K, Kassie A. Determinant of intention to receive COVID-19 vaccine among school teachers in Gondar City, Northwest Ethiopia. *PLoS ONE*. (2021) 16:e0253499. doi: 10.1371/journal.pone.0253499

19. Berihun G, Walle Z, Berhanu L, Teshome D. Acceptance of COVID-19 vaccine and determinant factors among patients with chronic disease visiting dessie comprehensive specialized hospital, Northeastern Ethiopia. *Patient Prefer Adherence*. (2021) 15:1795. doi: 10.2147/PPA.S324564

20. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey. *J Multidiscip Healthc.* (2020) 13:1657. doi: 10.2147/JMDH.S276771

21. Asmare G, Abebe K, Atnafu N, Asnake G, Yeshambel A, Alem E, et al. Behavioral intention and its predictors toward COVID-19 vaccination among people most at risk of exposure in Ethiopia: applying the theory of planned behavior model. *Hum Vaccin Immunother.* (2021) 17:4838-45. doi:10.1080/21645515.2021.2011651

22. Mesfin Y, Argaw M, Geze S, Zewdu BT. Factors associated with intention to receive COVID-19 vaccine among HIV-positive patients attending ART clinic in Southwest Ethiopia. *Patient Prefer Adherence*. (2021) 15:2731. doi: 10.2147/PPA.S342801

23. Zewude B, Habtegiorgis T. Willingness to take COVID-19 vaccine among people most at risk of exposure in Southern Ethiopia. *Pragm Observ Res.* (2021) 12:37. doi: 10.2147/POR.S313991

24. Belsti Y, Gela YY, Akalu Y, Dagnew B, Getnet M, Seid MA, et al. The willingness of the Ethiopian population to receive the COVID-19 vaccine. J Multidiscip Healthc. (2021) 14:1233. doi: 10.2147/JMDH.S312637

25. Al-Hanawi MK, Ahmad K, Haque R, Keramat SA. Willingness to receive COVID-19 vaccination among adults with chronic diseases in the Kingdom of Saudi Arabia. *J Infect Public Health.* (2021) 14:1489–96. doi: 10.1016/j.jiph.2021.08.002

26. Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China. *PLoS Negl Trop Dis.* (2020) 14:e0008961. doi: 10.1371/journal.pntd.0008961 27. Verger P, Scronias D, Dauby N, Adedzi KA, Gobert C, Bergeat M, et al. Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada, 2020. *Eurosurveillance*. (2021) 26:2002047. doi: 10.2807/1560-7917.ES.2021.26.3.2002047

28. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. *Lancet Reg Health Europe*. (2021) 1:100012. doi: 10.1016/j.lanepe.2020.100012

29. Elhadi M, Alsoufi A, Alhadi A, Hmeida A, Alshareea E, Dokali M, et al. Knowledge, attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a cross-sectional study. *BMC Public Health.* (2021) 21:1–21. doi: 10.1186/s12889-021-10987-3

30. Kumari A, Ranjan P, Chopra S, Kaur D, Upadhyay AD, Kaur T, et al. Development and validation of a questionnaire to assess knowledge, attitude, practices, and concerns regarding COVID-19 vaccination among the general population. *Diabetes Metab Synd Clin Res Rev.* (2021) 15:919-25. doi: 10.1016/j.dsx.2021.04.004

31. Kumari A, Ranjan P, Chopra S, Kaur D, Kaur T, Upadhyay AD, et al. Knowledge, barriers and facilitators regarding COVID-19 vaccine and vaccination program among the general population: a cross-sectional survey from one thousand two hundred and forty-nine participants. *Diab Metab Synd Clin Res Rev.* (2021) 15:987–92. doi: 10.1016/j.dsx.2021.04.015

32. CDC. Certain Medical Conditions and Risk for Severe COVID-19 Illness. (2020). Available online at: https://www.cdcgov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical/conditions/HTML (accessed August 10, 2021).

33. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death, and inequity worldwide. *Bull World Health Organ.* (2008) 86:140–6. doi: 10.2471/BLT.07.040089

34. Ayenigbara IO, Adegboro JS, Ayenigbara GO, Adeleke OR, Olofintuyi OO. The challenges to a successful COVID-19 vaccination program in Africa. *Germs.* (2021) 11:427. doi: 10.18683/germs.2021.1280

35. Mohamed NA, Solehan HM, Mohd Rani MD, Ithnin M, Che Isahak CI. Knowledge, acceptance, and perception on COVID-19 vaccine among Malaysians: a web-based survey. *PLoS ONE.* (2021) 16:e0256110. doi: 10.1371/journal.pone.0256110

36. Hammour KA, Farha RA, Manaseer Q, Al-Manaseer B. Factors affecting the public's knowledge about COVID-19 vaccines and the influence of knowledge on their decision to get vaccinated. *J Am Pharm Assoc.* (2022) 62:309–16. doi: 10.1016/j.japh.2021.06.021

37. Mirowsky J, Ross CE. Education, personal control, lifestyle, and health: a human capital hypothesis. *Res Aging.* (1998) 20:415–49. doi: 10.1177/0164027598204003

38. Omar DI, Hani BM. Attitudes and intentions towards COVID-19 vaccines and associated factors among Egyptian adults. J Infect Public Health. (2021) 14:1481-8. doi: 10.1016/j.jiph.2021.06.019

39. Mesesle M. Awareness and attitude towards COVID-19 vaccination and associated factors in Ethiopia: a cross-sectional study. *Infect Drug Resist.* (2021) 14:2193. doi: 10.2147/IDR.S316461

40. Gomes MG, Ferreira MU, Corder RM, King JG, Souto-Maior C, Penha-Gonçalves C, et al. Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. *J Theor Biol.* (2022) 540:111063. doi: 10.1016/j.jtbi.2022.111063

41. Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other Arab countries. *Vaccines*. (2021) 9:42. doi: 10.3390/vaccines9010042

42. Nindrea RD, Usman E, Katar Y, Sari NP. Acceptance of COVID-19 vaccination and correlated variables among global populations: a systematic review and meta-analysis. *Clin Epidemiol Global Health.* (2021) 12:100899. doi: 10.1016/j.cegh.2021.100899

43. Jiang N, Gu P, Sun X, Han H, Liu W, Song N, et al. Acceptance of COVID-19 vaccines in patients with chronic diseases: a cross-sectional study. *J Clin Nurs.* (2022). doi: 10.1111/jocn.16284

44. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med.* (2021) 27:225–8. doi: 10.1038/s41591-020-1124-9

45. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. *Clin Med.* (2020) 26:100495. doi: 10.1016/j.eclinm.2020.100495

46. Barreto TV, Rodrigues LC. Factors influencing childhood immunization in an urban area of Brazil. *J Epidemiol Comm Health.* (1992) 46:357-61. doi: 10.1136/jech.46.4.357